About eyal

This author has not yet filled in any details.
So far eyal has created 87 blog entries.

Quark Pharmaceuticals Reports Favorable Results from Phase II Clinical Trial Evaluating Investigational siRNA QPI-1002

July 28th, 2014|

San Francisco, CA – July 28, 2014 – Today, Quark Pharmaceuticals, Inc. reported data from a randomized, double-blinded, placebo-controlled multicenter Phase II clinical trial (QRK.006B; ClinicalTrials.gov identifier: NCT00802347) of QPI-1002, a synthetic chemically modified siRNA acting to reduce p53 RNA and protein levels, for the prophylaxis of delayed graft function (DGF) in deceased donor kidney […]

Quark will present at 2014 World Transplant Congress July 26-31st 2014

July 26th, 2014|

Treatment with QPI-1002, a Short Interfering (SI) RNA for the

Prophylaxis of Delayed Graft Function. V. Peddi,1 L. Ratner,2 M.

Cooper,2 O. Gaber,2 S. Feng,2 P. Tso,2 V. Bowers,2 R. Naraghi,2 K. Budde,2

Polinsky,3 E. Squiers,3 S. Erlich,3 Study Investigators Group.2 1CPMC,

San Francisco, CA; 2Multiple Institutions; 3Quark Pharmaceuticals,


Introduction: Delayed graft function (DGF) can adversely affect deceased donor

renal transplant […]

Quark Announces Completion of Phase II Trial Evaluating QPI-1002 for Prevention of Delayed Graft Function in Kidney Transplant Patients

July 1st, 2014|

Results to be presented at the World Transplant Conference on July 28, 2014

Fremont, CA, July 1, 2014 – Quark Pharmaceuticals, Inc. today reported completion of a randomized, placebo-controlled multicenter Phase II trial of QPI-1002 for the prophylaxis of delayed graft function (DGF) in ESRD dialysis-dependent patients undergoing deceased donor kidney transplantation. The results of the […]

Quark Announces First Patient Dosed in a Phase IIa Trial Evaluating QPI-1007 for Neuroprotection in Patients with Acute Primary Angle Closure Glaucoma

June 25th, 2014|


June 25, 2014 – 9:00am EST

Quark Pharmaceuticals, Inc. today announced that the first patient has been dosed in a double-masked, randomized sham controlled Phase IIa safety, tolerability and pharmacokinetics study of Quark’s proprietary neuroprotective agent QPI-1007 when administered by single intravitreal (IVT) injection in patients suffering an acute attack of primary angle closure glaucoma (PACG). […]

Quark will present at TIDES: Oligonucleotide Therapeutics Discovery. Providence, RI, May 12-15, 2014.

April 12th, 2014|

Use of siRNA for Treatment of Inner Ear Diseases.

Quark Pharmaceuticals and Suzhou Ribo Life Science Raise Nearly RMB 45 Million for Newly Established Chinese Joint Venture

January 7th, 2014|


Kunshan, China, January 7, 2014 – Kunshan RiboQuark Pharmaceutical Technology Co., Ltd. (“RiboQuark”), a Chinese-foreign equity joint venture and clinical stage pharmaceutical company, established by Suzhou Ribo Life Science Co., Ltd. (“Ribo”) and Quark Pharmaceuticals Inc., announced today that it has raised nearly RMB 45 million in a series A financing round. The financing was […]

Biocon and Quark Pharmaceuticals Collaborate to Develop Novel siRNA based Therapeutics

December 18th, 2013|

Bangalore, India, and Fremont, CA, December 18, 2013  

Biocon Ltd, Asia’s premier biotechnology company, and Quark Pharmaceuticals, Inc,. a world leader in the discovery and development of siRNA-based therapeutics, announced today that they have entered into a Licensing  & Collaboration agreement for the development of  a range of siRNA ( small interfering RNA)  based novel therapeutics.

This […]

Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007

January 4th, 2012|

Fremont, CA January 4, 2012, — Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced interim results from the first two cohorts of its Open Label, first-in-human Phase I clinical study of QPI-1007, the Company’s proprietary synthetic siRNA drug candidate for ocular neuroprotection, in patients with recent onset […]

In a Phase 2 Study PF-04523655 (RTP801I-14) Showed Improved Vision Over Standard of Care in Patients with Diabetic Macular Edema at 12 Months

March 18th, 2011|

Fremont, CA March 18, 2011, – Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, , today announced that it has received results from a prospective randomized Phase 2 trial, the DEGAS study. This study evaluated the safety and efficacy of PF-04523655 (RTP801I-14) in patients with diabetic macular edema […]

Rutgers Offers Hope in New Treatment for Spinal Cord Injuries

March 3rd, 2011|

May 03, 2011, – Rutgers researchers have developed an innovative new treatment that could help minimize nerve damage in spinal cord injuries, promote tissue healing and minimize pain.
After a spinal cord injury there is an increased production of a protein (RhoA) that blocks regeneration of nerve cells that carry signals along the spinal cord and […]